These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36058142)

  • 1. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies.
    Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z
    Crit Rev Oncol Hematol; 2024 Aug; 200():104204. PubMed ID: 37984588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of immune checkpoint inhibitors in colorectal cancer.
    Wang L; Huang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
    Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
    Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
    Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
    Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
    Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
    Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
    Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
    EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
    Huyghe N; Baldin P; Van den Eynde M
    Gastroenterol Rep (Oxf); 2020 Feb; 8(1):11-24. PubMed ID: 32104582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
    Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
    Chen JT; Zhou YW; Han TR; Wei JL; Qiu M
    Front Immunol; 2023; 14():1269341. PubMed ID: 38022667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
    Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
    Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
    Wu Q; Wang Z; Luo Y; Xie X
    BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2018 Dec; 17(4):258-273. PubMed ID: 30072278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
    Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
    Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
    Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
    Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
    Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
    Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.
    Marmorino F; Boccaccino A; Germani MM; Falcone A; Cremolini C
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.